Iveric Bio Inc
F:O2T
Iveric Bio Inc
Research & Development
Iveric Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Iveric Bio Inc
F:O2T
|
Research & Development
-$136.5m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-33%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Iveric Bio Inc
Glance View
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 37 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). The company is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The firm is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.
See Also
What is Iveric Bio Inc's Research & Development?
Research & Development
-136.5m
USD
Based on the financial report for Mar 31, 2023, Iveric Bio Inc's Research & Development amounts to -136.5m USD.
What is Iveric Bio Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-33%
Over the last year, the Research & Development growth was -53%. The average annual Research & Development growth rates for Iveric Bio Inc have been -44% over the past three years , -27% over the past five years , and -33% over the past ten years .
